Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel

J E Cortes1, R Pazdur

  • 1Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External control arms in oncology: current use and future directions.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Docetaxel, an antineoplastic taxoid, shows significant anticancer activity across various neoplasms. Its primary dose-limiting toxicity is neutropenia, with mucositis also being a notable side effect.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Docetaxel is a taxoid antineoplastic agent.
  • It functions by promoting microtubule assembly and preventing depolymerization.

Purpose of the Study:

  • To review the preclinical and clinical profiles of docetaxel.
  • To detail its activity, tolerability, and pharmacokinetics.

Main Methods:

  • Literature review and analysis of manufacturer's data.
  • Evaluation of preclinical, Phase I, and Phase II study results.

Main Results:

  • Docetaxel demonstrated activity in breast, lung, ovarian, head and neck, gastric cancers, melanoma, and soft tissue sarcomas.
  • Dose-limiting toxicity included neutropenia and mucositis.

Related Experiment Videos

  • Hypersensitivity reactions, neurotoxicities, and alopecia were also observed but manageable.

    • Conclusions:

    • Docetaxel exhibits consistent and significant activity in various cancers.
    • Ongoing trials are evaluating combination therapies and addressing side effects.